Beta-lactum antibiotic-tarocin fixed dose combination - Prokaryotics
Alternative Names: β-lactum antibiotic-tarocin fixed dose combination - ProkaryoticsLatest Information Update: 28 Aug 2026
At a glance
- Originator Prokaryotics
- Developer Prokaryotics; University of Florida
- Class Antibacterials
- Mechanism of Action Bacterial outer membrane protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (PO)
- 08 Jul 2022 Prokaryotics receives SBIR phase IIB grant from National Institute of Allergy and Infectious Diseases for beta-lactum antibiotic-tarocin fixed dose combination in Staphylococcal infections
- 08 Jul 2022 Preclinical trials in Staphylococcal infections in USA, prior to July 2022 (PO)